BIO.News Newsletter

Starting the week in Europe, with the U.K. approval of the Merck-Ridgeback COVID-19 pill and ongoing climate discussions. Meanwhile, an International Council of Biotechnology Associations (ICBA) delegation (including BIO) is in Geneva to discuss how the industry is leveraging global partnerships to produce billions of vaccines by mid-2022 and share new technologies with the globe—more on that to come. (605 words, 3 minutes, 1 second)

The House could vote today on the Build Back Better agenda, which includes a “rushed and highly politicized” drug pricing deal—here’s what BIO says about it, plus how to reduce emissions in the health care supply chain and thoughts on how to better support vulnerable sickle cell patients. (796 words, 3 minutes, 58 seconds) New look, same Good Day BIO. Our readers' views are important to us. Tell us your thoughts about how the new template affects your reading experience.

House Democrats’ drug pricing proposal could come up for a vote today or tomorrow—putting new cures and investment in R&D on the line. We have the latest developments from D.C., plus what happened in key state races on Tuesday. (858 words, 4 minutes, 17 seconds) New look, same Good Day BIO. Our readers' views are important to us. Tell us your thoughts about how the new template affects your reading experience.

It’s a busy Wednesday with news of a drug pricing deal and authorization of COVID vaccines for kids aged 5-11. We have details, plus BIO’s calls for climate-smart agriculture during COP26. (815 words, 4 minutes, 4 seconds) New look, same Good Day BIO. Our readers' views are important to us. Tell us your thoughts about the new template and how it affects your reading experience, so we can be sure it works for you!

As COP26 continues, we look at how food manufacturers are utilizing regenerative farming to make more sustainable sweets. Plus, everyone’s talking about “supply chains,” so we examine the impact of logjams on the pharmaceutical sector. (727 words, 3 minutes, 38 seconds) New look, same Good Day BIO. Our readers' views are important to us. Tell us your thoughts about the new template and how it affects your reading experience, so we can be sure it works for you!

It’s a critical week for both drug price controls and climate. Here’s what you need to know and how you can take action for patients and the planet. (738 words, 3 minutes, 41 seconds) New look, same Good Day BIO. Our readers' views are important to us. Tell us your thoughts about the new template and how it affects your reading experience, so we can be sure it works for you!

COP26 begins this weekend, and we’re wrapping up the Patient and Health Advocacy Summit with World Psoriasis Day and why patient stories matter. And, yeah, we buried the lede—there’s news on drug price controls at the end. (836 words, 4 minutes, 10 seconds)Also, this isn't a Halloween costume, it's our new look which officially rolls out Monday!

We recap the Patient and Health Advocacy Digital Summit Day 1 with lessons learned about patient data, COVID-19, and STEM education. Plus, Sen. Debbie Stabenow (D-MI) writes about the importance of climate-smart forestry and ag. (682 words, 3 minutes, 24 seconds)P.S. With BIO's new branding unveiled earlier this year at BIO Digital, we felt it was time for a little revamping around here, too. Tomorrow, we'll have a sneak peek at GoodDay's BIO's new look, hitting inboxes Monday, November 1!

BIO’s Patient and Health Advocacy Digital Summit begins at 12 PM ET—we tell you how to follow along. In the news, we have a recap of yesterday’s House Agriculture hearing on biotechnology as well as a look at two proposed bills that could incentivize antibiotic R&D and boost pandemic preparedness. (898 words, 4 minutes, 29 seconds)

Ahead of BIO’s Patient Health & Advocacy Digital Summit, the I am BIO Podcast features two powerful patient stories—with advice for patients and policymakers. And it’s almost Halloween—but we explain why you don’t need to be afraid of GMOs and gene editing. (754 words, 3 minutes, 46 seconds)